Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1138
Shown on this page
12
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within NYU Langone Health, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 409–420 of 1,138 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

NCT01695941
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Alisertib, Bortezomib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
New York, New York • The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Phase 2 Interventional

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

NCT07801664
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Deprivation Therapy (ADT), Radiotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Active, not recruiting Phase 2 Interventional

Neuroblastoma Maintenance Therapy Trial

NCT02679144
Site status not listed — check the official record
View directory record Official record
Conditions
Neuroblastoma
Interventions
Difluoromethylornithine (DFMO)
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
1 Year to 30 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2033
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Active, not recruiting No phase listed Observational

Surveillance HeartCare® Outcomes Registry

NCT03695601
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Standard of Care
Other
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Active, not recruiting Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

NCT03313778
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors
Interventions
mRNA-4157, Pembrolizumab, SoC Treatment
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT07285694
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
AB-3028
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Phase 1 Interventional

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Interventions
BBO-8520, Pembrolizumab, BBO-10203
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

NCT04942210
Site status not listed — check the official record
View directory record Official record
Conditions
Yellow Fever, Healthy Volunteers
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
11
States / cities
Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Stuttering and Neuromodulation

NCT07222163
Status at this site: Recruiting
View directory record Official record
Conditions
Stuttering
Interventions
Soterix Medical 1x1 tDCS system, Speech therapy sessions
Device · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NCT05080673
Status at this site: Recruiting
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
45 Years to 70 Years
Enrollment
9,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2065
U.S. locations
478
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT05174169
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1037
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 4:08 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Interventions
KIN-2787, KIN-2787 and binimetinib
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 4:08 PM EDT

About this NYU Langone Health institution page

What this page lists
ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.